Beta Bionics Inc (NASDAQ:BBNX) does about 507.24K shares in volume on a normal day but saw 1212445 shares change hands in the recent trading day. The company now has a market cap of 604.44M USD. Its current market price is $13.94, marking a decrease of -4.26% compared to the previous close of $14.56. The 52 week high reached by this stock is $24.50 whilst the lowest price level in 52 weeks is $8.89.
Beta Bionics Inc (BBNX) has a 20-day trading average at $17.53 and the current price is -43.10% off the 52-week high compared with 56.81% distance from its 52-week low. If we look at the stock’s price movements over the week, volatility stands at 7.42%, which increases to 8.37% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 35.21 to suggest the stock is neutral.
The consensus objective for the share price is $23.56, suggesting that the stock has a potential upside of 40.83% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 16, 2025 when Truist initiated the stock to “Buy” and issued a price target of $26. Wolfe Research initiated its price target at $20.
The current price level is -20.48%, -7.20%, and -12.60% away from its SMA20, SMA50, and SMA200 respectively, with the BBNX price moving above the 50-day SMA on current market day. Beta Bionics Inc (BBNX) stock is down -11.32% over the week and -19.14% over the past month. Its price is -41.01% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.47 and -2.24 for whole year. Expected sales for next quarter are $21.62M, which analysts say will come at $84.74M for the current fiscal year and next year at $116.39M. In addition, estimates put the company’s current quarterly revenue at an average of $19.69M.
To reach the target analysts have set, the stock logically needs to grow 40.83 percent from here.
Outstanding shares total 43.35M with insiders holding 6.51% of the shares and institutional holders owning 98.41% of the company’s common stock. Price to book ratio is 1.93.
